治疗前肌少症对头颈部癌症患者总生存期的预后价值：系统综述。

IF 2.2 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

International journal of oral and maxillofacial surgery Pub Date : 2025-01-01 DOI:10.1016/j.ijom.2024.07.008

A. Syziu, A. Schache

{"title":"治疗前肌少症对头颈部癌症患者总生存期的预后价值：系统综述。","authors":"A. Syziu, A. Schache","doi":"10.1016/j.ijom.2024.07.008","DOIUrl":null,"url":null,"abstract":"<div><div>The aim of this study was to determine the prognostic value of pre-treatment sarcopenia, defined radiologically (cervical (C3) or lumbar (L3) region), in adult head and neck cancer (HNC) patients undergoing treatment with curative intent. A systematic search of the PubMed and Scopus databases was performed up to March 2024. Inclusion criteria were adult patients with locally advanced HNC, sarcopenia defined radiologically at the C3 and/or L3 level, and patients receiving primary treatment with curative intent. Risk of bias was assessed using the ROBINS-I tool non-randomised studies. Thirty studies involving a total of 6924 adult patients with HNC were included in this review. Pre-treatment sarcopenia was significantly associated with worse overall survival outcomes in 26 of the 30 studies (87%), across all treatment modalities with curative intent. The most frequent sex-specific SMI cut-off values were <52.4 cm<sup>2</sup>/m<sup>2</sup> for males and <38.5 cm<sup>2</sup>/m<sup>2</sup> for females. The findings of this review suggest that sarcopenia is a strong prognostic factor of overall survival in HNC patients undergoing primary curative treatment. Sarcopenia evaluation appears to be a good prognostic marker in the HNC population. Future nutritional interventional studies might focus on reversing the muscle loss and improving overall outcomes in identified sarcopenic individuals.</div></div>","PeriodicalId":14332,"journal":{"name":"International journal of oral and maxillofacial surgery","volume":"54 1","pages":"Pages 1-11"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The prognostic value of pre-treatment sarcopenia in overall survival in head and neck cancer patients: a systematic review\",\"authors\":\"A. Syziu, A. Schache\",\"doi\":\"10.1016/j.ijom.2024.07.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The aim of this study was to determine the prognostic value of pre-treatment sarcopenia, defined radiologically (cervical (C3) or lumbar (L3) region), in adult head and neck cancer (HNC) patients undergoing treatment with curative intent. A systematic search of the PubMed and Scopus databases was performed up to March 2024. Inclusion criteria were adult patients with locally advanced HNC, sarcopenia defined radiologically at the C3 and/or L3 level, and patients receiving primary treatment with curative intent. Risk of bias was assessed using the ROBINS-I tool non-randomised studies. Thirty studies involving a total of 6924 adult patients with HNC were included in this review. Pre-treatment sarcopenia was significantly associated with worse overall survival outcomes in 26 of the 30 studies (87%), across all treatment modalities with curative intent. The most frequent sex-specific SMI cut-off values were <52.4 cm<sup>2</sup>/m<sup>2</sup> for males and <38.5 cm<sup>2</sup>/m<sup>2</sup> for females. The findings of this review suggest that sarcopenia is a strong prognostic factor of overall survival in HNC patients undergoing primary curative treatment. Sarcopenia evaluation appears to be a good prognostic marker in the HNC population. Future nutritional interventional studies might focus on reversing the muscle loss and improving overall outcomes in identified sarcopenic individuals.</div></div>\",\"PeriodicalId\":14332,\"journal\":{\"name\":\"International journal of oral and maxillofacial surgery\",\"volume\":\"54 1\",\"pages\":\"Pages 1-11\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of oral and maxillofacial surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0901502724002212\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of oral and maxillofacial surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0901502724002212","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

摘要

本研究旨在确定接受根治性治疗的成年头颈癌（HNC）患者治疗前肌少症的预后价值，肌少症是通过放射学（颈椎（C3）或腰椎（L3）区域）定义的。我们对 PubMed 和 Scopus 数据库进行了系统检索，检索期截至 2024 年 3 月。纳入标准为局部晚期HNC成人患者、C3和/或L3水平放射学界定的肌少症患者以及接受根治性初治的患者。采用 ROBINS-I 工具评估非随机研究的偏倚风险。本综述共纳入了 30 项研究，涉及 6924 名 HNC 成年患者。在 30 项研究中，有 26 项研究（87%）发现治疗前肌少症与较差的总生存率显著相关，这些研究涉及所有以治愈为目的的治疗方式。最常见的性别特异性 SMI 临界值男性为 2/m2，女性为 2/m2。本综述的研究结果表明，对于接受初级根治性治疗的 HNC 患者来说，肌肉疏松症是影响总生存期的一个重要预后因素。在 HNC 患者中，肌少症评估似乎是一个很好的预后指标。未来的营养干预研究可能会侧重于逆转肌肉流失，改善已发现的肌少症患者的总体预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The prognostic value of pre-treatment sarcopenia in overall survival in head and neck cancer patients: a systematic review

The aim of this study was to determine the prognostic value of pre-treatment sarcopenia, defined radiologically (cervical (C3) or lumbar (L3) region), in adult head and neck cancer (HNC) patients undergoing treatment with curative intent. A systematic search of the PubMed and Scopus databases was performed up to March 2024. Inclusion criteria were adult patients with locally advanced HNC, sarcopenia defined radiologically at the C3 and/or L3 level, and patients receiving primary treatment with curative intent. Risk of bias was assessed using the ROBINS-I tool non-randomised studies. Thirty studies involving a total of 6924 adult patients with HNC were included in this review. Pre-treatment sarcopenia was significantly associated with worse overall survival outcomes in 26 of the 30 studies (87%), across all treatment modalities with curative intent. The most frequent sex-specific SMI cut-off values were <52.4 cm²/m² for males and <38.5 cm²/m² for females. The findings of this review suggest that sarcopenia is a strong prognostic factor of overall survival in HNC patients undergoing primary curative treatment. Sarcopenia evaluation appears to be a good prognostic marker in the HNC population. Future nutritional interventional studies might focus on reversing the muscle loss and improving overall outcomes in identified sarcopenic individuals.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International journal of oral and maxillofacial surgery 医学-外科

CiteScore

5.10

自引率

4.20%

发文量

318

审稿时长

78 days

期刊介绍： The International Journal of Oral & Maxillofacial Surgery is one of the leading journals in oral and maxillofacial surgery in the world. The Journal publishes papers of the highest scientific merit and widest possible scope on work in oral and maxillofacial surgery and supporting specialties. The Journal is divided into sections, ensuring every aspect of oral and maxillofacial surgery is covered fully through a range of invited review articles, leading clinical and research articles, technical notes, abstracts, case reports and others. The sections include: • Congenital and craniofacial deformities • Orthognathic Surgery/Aesthetic facial surgery • Trauma • TMJ disorders • Head and neck oncology • Reconstructive surgery • Implantology/Dentoalveolar surgery • Clinical Pathology • Oral Medicine • Research and emerging technologies.